Khiron Life Science Society. (“Khiron” or the “Company”) (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core businesses in Latin America and Europe, is pleased to announce that President Chris Naprawa will present live at the 4th Virtual Conference Canaccord Genuity Global Cannabis Annual Report Tuesday, May 12, 2020 at 11:40 a.m. ET (8:40 a.m. PT).
Canaccord Genuity’s annual Global Cannabis Conference is an investor-focused virtual event that engages a global network of leading players in the cannabis industry. To join Mr. Naprawa’s presentation, visit: http://wsw.com/webcast/canaccord39/khrn
Khiron Recent Highlights
- Receives first medical cannabis prescriptions for UK patients participating in Project Twenty21, Europe’s largest study on the efficacy and tolerability of medical cannabis
- Signature of an exclusive agreement with Medlive, a distributor serving 3,000 clinics and hospitals in Brazil, the country which represents the largest addressable market in Latin America with a population of approximately 212 million inhabitants
- signs a medical cannabis distribution agreement in Colombia with Locatel, a pharmacy, health products and medical equipment retailer with a database of over 2 million patients in Colombia.
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is the leading integrated medical cannabis company in Latin America. Khiron has main activities in Latin America, as well as operations in North America and Europe, and is authorized in Colombia for the cultivation, production, national distribution and international export of medical cannabis based on tetrahydrocannabinol (THC ) and cannabidiol (CBD). The company offers best-in-class regulatory compliance, has the first approved line of CBD cosmetic products in Colombia, and is fully licensed to manufacture high- and low-THC medical cannabis and fill low-THC medical cannabis prescriptions. THC in the country.
With a focused regional strategy and patient-centric approach, the company combines global scientific expertise, agricultural advantages, branded market entry experience and education to drive prescribing and brand loyalty. to treat priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. The company is led by co-founder and CEO Alvaro Torres, along with an experienced management team and a capable board that includes former Mexico President Vicente Fox.
Visit Khiron online at www.khiron.ca and on Instagram @khironlife
This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on any analyses, expectations or statements made by third parties regarding Khiron, its securities or its financial or operating results (as applicable). Although Khiron believes that the expectations reflected in the forward-looking statements in this press release are reasonable, these forward-looking statements are based on expectations, factors and assumptions regarding future events which may prove to be inaccurate and are subject to numerous risks and uncertainties. , some of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or liability, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
This press release does not constitute an offer to sell or a solicitation of an offer to buy securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “United States Securities Act”) or any state securities law and may not be offered or sold in the United States or to US Persons (as that term is defined in Regulation S of the US Securities Act) unless registered under the US Securities Act and applicable state laws on securities or an exemption from such registration is available
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
The post office Khiron to Present at Canaccord Genuity’s Virtual Global Cannabis Conference appeared first on Investment News Network.
#Khiron #Present #Canaccord #Genuitys #Global #Cannabis #Virtual #Conference #Cannabis #Hemp #Blog